Genor Biopharma Holdings Limited

HKSE 6998.HK

Genor Biopharma Holdings Limited Revenue for the year ending December 31, 2023: USD 0.00

Genor Biopharma Holdings Limited Revenue is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Genor Biopharma Holdings Limited Revenue for the year ending December 31, 2022 was USD 2.31 M, a 0.00% change year over year.
  • Genor Biopharma Holdings Limited Revenue for the year ending December 31, 2021 was USD 0.00, a -100.00% change year over year.
  • Genor Biopharma Holdings Limited Revenue for the year ending December 31, 2020 was USD 1.58 M, a -15.47% change year over year.
  • Genor Biopharma Holdings Limited Revenue for the year ending December 31, 2019 was USD 1.87 M, a 87.12% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
HKSE: 6998.HK

Genor Biopharma Holdings Limited

CEO Dr. Feng Guo Ph.D.
IPO Date Oct. 7, 2020
Location China
Headquarters Building 3
Employees 28
Sector Health Care
Industries
Description

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Similar companies

6855.HK

Ascentage Pharma Group International

USD 5.19

2.25%

1877.HK

Shanghai Junshi Biosciences Co., Ltd.

USD 1.39

3.41%

StockViz Staff

January 15, 2025

Any question? Send us an email